Norbuprenorphine (NBUP) is the major active metabolite of buprenorphine (BUP) which is commonly used to treat opiate addiction during pregnancy; it possesses 25% of BUP's analgesic activity and 10 times BUP's respiratory depression effect. To optimize BUP's dosing regimen during pregnancy with better efficacy and safety, it is important to understand how pregnancy affects NBUP disposition. In this study, we examined the pharmacokinetics of NBUP in pregnant and non-pregnant mice by administering the same amount of NBUP through retroorbital injection. We demonstrated that the systemic clearance (CL) of NBUP in pregnant mice increased ~2.5-fold compared with non-pregnant mice. Intrinsic CL of NBUP by glucuronidation in mouse liver microsomes from pregnant mice was ~2 times greater than that from non-pregnant mice. Targeted LC-MS/MS proteomics quantification revealed that hepatic Ugt1a1 and Ugt2b1 protein levels in the same amount of total liver membrane proteins were significantly increased by ~50% in pregnant mice versus non-pregnant mice. After scaling to the whole liver with consideration of the increase in liver protein content and liver weight, we found that the amounts of Ugt1a1, Ugt1a10, Ugt2b1, and Ugt2b35 protein in the whole liver of pregnant mice were significantly increased ~2-fold compared to non-pregnant mice. These data suggest that the increased systemic CL of NBUP in pregnant mice is likely caused by an induction of hepatic Ugt expression and activity. The data provide a basis for further mechanistic analysis of pregnancyinduced changes in the disposition of NBUP and drugs that are predominately and extensively metabolized by Ugts.
DMD # 76745 Introduction
Opioid addiction cases in the United States continue to escalate as a top national health crisis. Opioid addiction as a result of prescription opioid use during pregnancy accounted for 28% of admissions of pregnant women to treatments of drug abuse from 1992 to 2012 (Martin et al., 2015) . Untreated substance abuse during pregnancy increases the risk for adverse pregnancy outcomes and fetal anomalies. Due to the dual risk to the mother and fetus, opioid addiction treatment is an increasing priority for this understudied population. Although methadone as a medication-assisted treatment for opioid addiction is the gold standard, recent research supports the use of buprenorphine (BUP) for opioid treatment during pregnancy. Randomized clinical trials comparing methadone and BUP indicate that both medications are effective in preventing relapse in opioid-dependent patients (Stotts et al., 2009) . Moreover, increasing clinical research suggest that the use of BUP results in more favorable maternal and fetal outcome (shorter hospital stay, shorter duration of treatment for neonatal abstinence syndrome) compared to methadone (Jones et al., 2010) . Fig. 1) is a semisynthetic μ-opioid receptor agonist and κ-opioid and δ-opioid receptor antagonist. BUP is metabolized by cytochrome P450 3A (CYP3A) through Ndealkylation to norbuprenorphine (NBUP) (Fig. 1) . NBUP is the major active metabolite of BUP in humans and rodents with ~25% of BUP's intrinsic analgesic activity (Brown et al., 2012) .
BUP (
Both BUP and NBUP can be further metabolized primarily to buprenorphine-3-β-D-glucuronide and norbuprenorphine-3-β-D-glucuronide (NBUP-G, Fig. 1 ), respectively, by uridine 5'-diphospho-glucuronosyltransferases (UGTs) (Brown et al., 2011) . A mass balance study on BUP revealed that NBUP and NBUP-G exposure accounted for >10% of the total BUP plasma exposure (Jones RT, 1997) . As per FDA Safety Testing of Drug Metabolite Guidance for
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Industry, human metabolites formed at >10% of total drug-related exposure at steady state could raise safety concerns (U.S. Food and Drug Administration, 2016) . Given the fact that NBUP can produce respiratory depression 10 times more potent than BUP in rodents (Yassen et al., 2007) and possibly in infants (Kim et al., 2012) , drug-drug interactions with BUP leading to elevated systemic concentrations of NBUP may contribute to an increased risk of neurorespiratory depression. Therefore, in order to optimize BUP's dosing regimen with better efficacy and safety, we need to understand the disposition and pharmacokinetics (PK) of not only BUP but also NBUP. While the disposition of BUP has been extensively studied (Chiang and Hawks, 2003; Hand et al., 1990; Kacinko et al., 2008) and the dose-normalized plasma AUC of BUP has been shown to be significantly decreased about 2-fold by pregnancy in pregnant women (Bastian et al., 2017) , much less is known about NBUP in this regard, particularly during pregnancy. Pregnancy causes drastic changes in hormone production, such as elevated levels of estrogens, progesterone, cortisol and growth hormones, which may be responsible for altered expression and activity of drug metabolizing enzymes (Anderson, 2005) . As a result, some UGTs may be upregulated by pregnancy (Chen et al., 2009; Jeong et al., 2008; Wen et al., 2013) . Given that NBUP is extensively metabolized by UGTs (Chang and Moody, 2009; Rouguieg et al., 2010) , whether the disposition of NBUP is altered by pregnancy due to induction of glucuronidation warrants investigation. No such studies have been reported so far.
Therefore, in this study, we first determined the PK of NBUP and NBUP-G in pregnant and non-pregnant mice. We then demonstrated whether the intrinsic clearance of NBUP by glucuronidation and Ugt protein expression in the mouse liver were increased by pregnancy. The data obtained will facilitate mechanistic understanding of changes in the disposition of NBUP DMD # 76745 6 during pregnancy, which could be important to inform therapeutic strategies in pregnant women for BUP and drugs that are primarily metabolized by UGTs.
Materials and Methods
Materials. NBUP and NBUP-G used for animal studies were provided by the National Institute on Drug Abuse (Bethesda, MD). NBUP, norbuprenorphine-d3 (NBUP-d3) and NBUP-G used for analytical calibrations in LC-MS/MS assays were from Cerilliant (Round Rock, TX 
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were maintained under 12-hour light/dark cycles, and food and water were provided ad libitum.
Female mice were mated with male mice of the same age overnight using a female to male ratio of 2:1. Gestation day (gd) 1 was defined as the presence of a sperm plug following overnight housing. Increase in body weight was used as an indicator for healthy pregnancy. Body weight was recorded on the day of dosing. Pregnant mice used in this study were on gd 15, which approximately corresponds to the late second trimester in humans. Non-pregnant female mice were compared to pregnant mice throughout this study with respect to the PK of NBUP and its derived glucuronidated metabolite NBUP-G.
The animal study protocol was essentially the same as previously described . Briefly, NBUP was dissolved in a solution that contained 0.5 % (v/v) dimethyl sulfoxide, 10% (v/v) ethanol, 39.5% (v/v) saline, and 50% (v/v) polyethylene glycol 400 at a concentration of 0.5 mg/ml. Under 2-5% isoflurane anesthesia, each pregnant or non-pregnant mouse was administered the same dose of 33 μg of NBUP by retro-orbital injection. This dose was selected based on literature data about elicitation of a significant decrease in respiratory rate in mice and the achievement of plasma concentration of NBUP in mice (Brown et al., 2012) that was comparable to that observed in pregnant women in the late second and early third trimesters (Concheiro et al., 2011) . Previous pharmacokinetic studies showed that the half-life of NBUP in rodent was approximately 0.9 hour (Ohtani et al., 1994) . We therefore administered NBUP to pregnant and non-pregnant female mice and collected blood at time points up to 720 min which is longer than 10 half-lives. Thus, at various times (2, 30, 120, 240, 480 and 720 min) after NBUP administration, mice (n = 3 per time point) were sacrificed under anesthesia by cardiac puncture. Blood samples were collected in heparinized microcentrifuge tubes (BD Bioscience, San Jose, CA) and centrifuged at 1,000 × g for 10 min at 4ºC. Plasma was collected and stored at
8 -80ºC until use. At the first two time points, blood samples were collected under the same anesthetic used for the NBUP administration. Liver tissues were collected at the same time points as blood samples. NBUP and NBUP-G in plasma samples were quantified by a validated LC-MS/MS assay as previously described .
Plasma protein binding of NBUP. Protein binding of NBUP in mouse plasma was determined by ultrafiltration using Microcon-10 kDa Centrifugal Filter with Ultracel-10 membranes (EMD Millipore Corporation, Billerica, MA) at ~1 µM which is the C max of NBUP in pregnant mice determined in this study. Plasma protein binding by ultrafiltration method was performed as previously described (Shuster et al., 2014) . Briefly, NBUP in methanol was aliquoted into 1.5 ml Eppendorf tubes and evaporated to dryness. Plasma from pregnant or non-pregnant mice (gd 15) was added to each tube to a total volume of 220 µl. Samples were briefly vortexed and allowed to equilibrate for 30 min at 37°C. Two 100-µl aliquots from each sample were transferred to ultrafiltration cartridges, equilibrated for 30 min at 37°C, and centrifuged at 1000 × g for 20 min.
NBUP in three microliters of filtrate and unfiltered plasma was quantified by LC-MS/MS as previously described . The fraction unbound (f u ) of NBUP was calculated as the percentage of the concentration of NBUP in filtrate to the concentration of NBUP in corresponding unfiltered plasma. This plasma protein binding study was repeated with 6 independent experiments with each done in in triplicate.
NBUP-G formation kinetics in mouse liver microsomes from pregnant and non-pregnant mice.
Microsomes were prepared from mouse liver tissues isolated from pregnant and non-pregnant mice as previously described (Shuster et al., 2014) . Briefly, every 1 g of mouse liver tissue was homogenized in 3 ml of homogenization buffer (50 mM KPi buffer containing 0.25 M sucrose and 1 mM EDTA) using an Omni Bead Ruptor Homogenizer (Omni International). The
homogenate was centrifuged at 15,000 × g for 30 min at 4°C, and the supernatant was centrifuged at 120,000 × g for 70 min at 4°C. Microsomal pellets were re-suspended in the washing buffer (10 mM KPi, 0.1 mM KCl, and 1 mM EDTA, pH 7.4) and then centrifuged at 120,000 × g for 70 min at 4°C. Microsomal pellets were finally resuspended in 1 ml of storage buffer (50 mM KPi, 0.25 M sucrose, and 10 mM EDTA, pH 7.4), and stored at −80°C until use.
Microsomal protein concentrations were determined using the BCA protein assay. 
Protein quantification of Ugts in pregnant and non-pregnant mouse livers by LC-MS/MS.
Protein quantification of murine Ugt isoforms (Ugt1a1, Ugt1a6, Ugt1a8, Ugt1a10, Ugt2b1, and Ugt2b35) in pregnant and non-pregnant mouse livers was carried out using a surrogate peptidebased LC-MS/MS method as previously described (Prasad et al., 2014) . One or two signature peptides unique for the Ugt isoforms (Table 1) were selected for quantification of each enzyme based on previously reported criteria (Prasad et al., 2014 (Table 1 ). Prior to protein quantification, liver tissues from pregnant and non-pregnant mice were homogenized in extraction buffer I of the ProteoExtract native membrane protein extraction kit containing protease inhibitor cocktail according to the manufacturer's instruction. The resulting homogenate was centrifuged at 16,000 × g for 15 min and the supernatant was discarded. The pellet was resuspended in 1 ml of extraction buffer II with protease inhibitor cocktail and incubated with gentle shaking for 30 min at 4°C, followed by centrifugation at 16,000 × g for 15 min at 4°C. The concentration of total isolated membrane proteins in the supernatant was then determined using the BCA protein assay. The supernatant was diluted to protein concentration of 2 µg per µl. The total membrane proteins were reduced, denatured, alkylated, desalted and digested as per our previously reported protocol (Boberg et al., 2017) . Twenty µl of heavy The Ugts were quantified using optimized parameters (Table 1) formic acid) and 3% B (acetonitrile containing 0.1% v/v formic acid) held for 3 min, followed by four steps of linear gradient of mobile phase B of 3% to 13%, 13% to 25%, 25% to 50% and 50%
to 80% over 3-10 min, 10-20 min, 20-24 min and 24.1-25 min, respectively. This was followed by a washing step using 80% mobile phase B for 0.9 min, and re-equilibration for 4.9 min. The parent to product ion transitions for the analyte peptides and their respective SIL peptides were monitored using optimized LC-MS/MS parameters (Table 1) in ESI positive ionization mode.
For data analysis, peak response of multiple reaction monitoring (MRM) transition from each peptide was averaged and the area ratio of analyte peptide versus internal standard (IS) peptide was obtained. Relative protein expression of individual Ugt was presented as the peak area ratio of analyte peptide over that of the internal standard (IS) peptide and, then the ratio was normalized to the corresponding ratio of respective Ugt in the pooled liver tissue homogenates.
Pooled tissue homogenates were pooled individual liver samples from the same experiment.
Normalization to internal standard was necessary to reduce variations between sample preparations. Normalization to pooled tissue homogenates was used as batch to batch quality controls. The experiments were repeated with 3 independent mouse livers from each group (pregnant and non-pregnant mice) with the same amount of total membrane protein for trypsin Pharmacokinetic data analysis. The area under concentration-time curve (AUC 0-∞) values of plasma NBUP and NBUP-G were calculated using the linear trapezoidal method for both pregnant and non-pregnant mice. Since plasma concentrations of NBUP at 720 min were below the limit of quantification, data at 720 min were not used in the AUC calculation. Therefore, AUC 0-∞ was estimated by extrapolating from the time points at 120, 240 and 480 min. The AUC from 480 min to infinity accounted for less than 15% of total AUC 0-∞ . Because NBUP in plasma was sampled in different animals at each time point (one-point sampling), we performed the PK data analysis using a population-based bootstrap method as previously described previously (Shuster et al., 2014) . AUC 0-∞ and clearance (CL) were calculated. CL was calculated by dose divided by AUC 0-∞ . The 95% confidence intervals of the sample distributions were estimated by bootstrapping the concentration-time data for each group with modification (Mager and Goller, 1998) . Briefly, concentration-time data points from each dataset of interest were randomly sampled with replacement using the R program. This process was repeated 10,000 times to create 10,000 pseudo concentration-time profiles. The 95% confidence interval was the range of AUCs that encompassed the 2.5 th to the 97.5 th percentiles of the sample distribution. For each profile, concentrations at each time point were averaged and the PK parameters were calculated.
Confidence intervals of metabolite/parent AUC 0-∞ ratios were also estimated by bootstrapping 10,000 iterations of the paired metabolite to parent AUC ratios.
This article has not been copyedited and formatted. The final version may differ from this version. Statistical analysis. Quantitative assays were performed in triplicates and repeated at least three times. Data are presented as mean ± SD of three independent experiments. The 95% confidence intervals around each estimated PK parameters were determined using the non-parametric bootstrap method (Shuster et al., 2014) . Two-side p values were calculated using permutation tests with 10,000 replications (Shuster et al., 2014) . For comparisons of data in microsome incubations and proteomic studies, statistically significant differences were determined by unpaired Student's t-test. Differences with p values of < 0.05 were considered statistically significant.
Results
Pregnancy increased systemic clearance of NBUP. To demonstrate how pregnancy affects the disposition of NBUP, NBUP was administered to pregnant (gd 15) and non-pregnant mice by retro-orbital injection with the same dose of NBUP (33 μg) to each mouse. Maternal plasma concentrations of NBUP ( Fig. 2A and Fig. 2C ) and NBUP-G ( Fig. 2B and Fig. 2D ) in pregnant mice were significantly lower than those in non-pregnant mice. As a result, the plasma AUC 0-∞ of NBUP in pregnant mice was ~2.5 times lower than that in non-pregnant mice (p < 0.05) ( Table 2 ). The corresponding systemic CL of NBUP in pregnant mice was increased ~2.5-fold compared to that in non-pregnant mice (p < 0.05) ( Table 2) . Likewise, the plasma AUC 0-∞ of NBUP-G significantly decreased ~2.4-fold in pregnant mice compared to non-pregnant mice (Table 2 ). The NBUP-G/NBUP AUC 0-∞ ratio and plasma protein binding (f u ) of NBUP were not significantly affected by pregnancy (Table 2) . We noted that the plasma concentrations of NBUP-G, even at early time points (e.g., 2 min), were ~10 times greater than those of the parent compound NBUP in both pregnant and non-pregnant mice (Fig. 2) , suggesting that NBUP was rapidly and extensively metabolized to NBUP-G in mice. This finding is in agreement with their homology to human UGT isoforms that have been shown to metabolize NBUP (Mackenzie et al., 2005) and their moderate to high basal expression in female mouse livers (Buckley and Klaassen, 2007) . Due to the lack of selective antibodies and probe substrates for individual mouse Ugt isoforms, the use of immunoblotting or measurement of glucuronidation activity to demonstrate pregnancy-induced changes in expression or activity of individual mouse Ugts is not feasible. Moreover, LC-MS/MS based proteomics possesses superior accuracy, sensitivity, and reproducibility in quantification of proteins compared to conventional immunoblotting. Since we were primarily interested in pregnancy-induced changes in Ugt expression, only relative (not absolute) hepatic protein expression of individual Ugt isoforms between pregnant and nonpregnant mice was analyzed in this study.
Since 160 μg of total membrane proteins were used in each tryptic digestion, the data shown in Fig. 4 demonstrate changes in protein levels of individual Ugts quantified in the same amount of total membrane proteins used in tryptic digestion. Thus, Ugt1a1 (Fig. 4A ) and Ugt2b1
( Fig. 4B ) protein expression in pregnant mice were significantly increased by approximately 50% compared to non-pregnant mice. Pregnancy did not significantly affect protein expression of Ugt1a6, Ugt1a8, Ugt1a10, and Ugt2b35 ( Fig. 4C-4F ).
The yield of total membrane protein isolation and liver weight may be altered by pregnancy, affecting the total amount of Ugts in the whole liver. The yield of total membrane protein isolation from mouse liver was 0.08 ± 0.01 and 0.10 ± 0.02 µg per 1 mg of liver tissue for non-pregnant and pregnant mice, respectively. The liver weight was 1.3 ± 0.1 and 2.1 ± 0.1 g for non-pregnant and pregnant mice, respectively. After scaling the data of Fig. 4 to the whole liver, the protein levels of Ugt1a1, Ugt1a10, Ugt2b1, and Ugt2b35 were significantly induced approximately 2-2.5-fold by pregnancy (Fig. 5A-5D ). Pregnancy did not significantly affect the protein levels of Ugt1a6 and Ugt1a8 in the whole liver ( Fig. 5E and 5F ).
Discussion
The present study demonstrates that pregnancy significantly increases the systemic clearance of NBUP in a mouse model, which could be due to pregnancy-induced changes in factors important for NBUP disposition such as enhanced biliary excretion, induced hepatic metabolism, decreased plasma protein binding, or increased renal excretion. NBUP is a substrate of the efflux transporter P-glycoprotein and Ugts in the liver, and can be cleared by the kidney (Brown et al., 2012; Kacinko et al., 2009; Liao et al., 2017) . To date, there has been no evidence suggesting that pregnancy induces P-glycoprotein in the liver. The contribution of altered plasma protein binding can be ruled out as we showed that pregnancy did not significantly change plasma protein binding of NBUP in mice. Thus, the increase in NBUP clearance could be due to the combination of increased Ugt-mediated hepatic metabolism and increased renal excretion.
Kacinko et al. (Kacinko et al., 2009) showed that the amount of NBUP-G excreted in urine was 6 times the amount of NBUP after administration of BUP and the cumulative NBUP excreted in urine was minimal, suggesting that renal clearance of NBUP plays a minor role in the overall disposition of NBUP. However, since pregnancy is known to increase renal clearance of drugs (Jeyabalan and Conrad, 2007) , increased renal clearance of NBUP in pregnant mice versus nonpregnant mice cannot be ruled out. On the other hand, the data of NBUP-G formation in mouse liver microsomes suggest that induction of Ugt-mediated hepatic metabolism of NBUP is likely the primary cause of the increased systemic CL of NBUP during pregnancy. (Bastian et al., 2017; Fischer et al., 2014; Ohman et al., 2000) . An increase in the clearance of drugs can significantly decrease systemic drug concentrations and may lead to suboptimal therapeutic outcomes. It is thus critical to investigate if the increase in the clearance of these drugs during pregnancy is due to induction of UGT-mediated hepatic metabolism.
Results of this study suggest that the mouse model could possibly be suitable for such studies.
Nevertheless, caution should be taken when extrapolating data from mice to humans due to the lack of sufficient knowledge about species differences in functions, expression and tissue distribution of individual UGT/Ugt isoforms between humans and mice (Yang et al., 2017) .
Indeed, we showed in this study that the K m values of NBUP-G formation by Ugts in mouse liver were 6-7 times lower than the K m of human UGTs reported in a previous study (Chang and Moody, 2009 ).
This article has not been copyedited and formatted. The final version may differ from this version. We found that protein expression of Ugt1a1 and Ugt2b1 in total membrane proteins isolated form the mouse liver was significantly induced by pregnancy ( Fig. 4A and Fig. 4B ).
Induction of protein expression of mouse Ugts by pregnancy is consistent with mouse liver microsome incubation analysis which showed that pregnancy did not affect the K m of NBUP-G formation, but significantly increased the V max . It has been shown that that 17β-estradiol may upregulate human UGT1A4 via the estrogen receptor α (Chen et al., 2009) , and that progesterone induces human UGT1A1 (Jeong et al., 2008) possibly through the pregnane-X-receptor (Chen et al., 2012) . Whether other human UGT isoforms including UGT1A3, UGT2B7 and UGT2B17
could be induced by the pregnancy-related hormones is not known. The induction of UGT1A expression by pregnancy-specific hormones is in line with our protein quantification data.
However, our protein quantification data are not consistent with other published studies for murine Ugt1a1 (Chen et al., 2012; Wen et al., 2013) . Wen et al. (Wen et al., 2013) demonstrated that on gestation day 14, hepatic protein expression of Ugt1a1 in pregnant mice determined by immunoblotting was not significantly altered compared to that in non-pregnant mice. Chen et al.
(Chen et al., 2012) also showed by immunoblotting that hepatic Ugt 1a1 in mice was not induced by pregnancy. Changes in protein levels of Ugt1a1 in the previous studies could possibly have gone unnoticed given the low selectivity and sensitivity of immunoblotting in detecting changes in protein expression compared to the highly sensitive LC-MS/MS technique used in this study.
We noted that protein levels of Ugt1a1 and Ugt2b1 in total membrane protein extracts shown in Fig. 4 were increased by ~50% in pregnant mice versus non-pregnant mice. This 50% increase cannot fully explain the 2-fold increase in the systemic CL of NBUP. We figured that the increase in Ugt protein levels in total membrane protein extracts do not fully reflect the changes in the amount of Ugts expressed in the whole liver due to concomitant increase in membrane protein content and liver weight during pregnancy. Indeed, after scaling to the whole liver with consideration of the yield of membrane protein isolation and the change in liver weight during pregnancy, we found that the whole liver content of Ugt1a1, Ugt1a10, Ugt2b1 and Ugt2b35 increased 2-2.5-fold by pregnancy (Fig. 5 ). It appears that the increase in hepatic Ugt content can now explain the ~2-fold increase in the systemic CL of NBUP in pregnant mice versus non-pregnant mice. It is important to note that even though relative protein expression of some Ugts (Ugt1a10 and Ugt2b35) in total membrane proteins was not changed by pregnancy, the amount protein of these Ugts in the whole liver were still significantly increased by pregnancy due to increase in protein content and liver weight in pregnant mice versus nonpregnant mice. This should be taken into account in interpretation of pregnancy-induced PK changes for drugs metabolized by UGTs.
We showed that the plasma concentrations of NBUP-G were several times higher than those of NBUP over time in both pregnant and non-pregnant mice (Fig. 2) , suggesting that the systemic clearance of NBUP is much faster than that of NBUP-G. Furthermore, even though hepatic glucuronidation of NBUP is significantly induced by pregnancy, the AUC metabolite /AUC parent ratio remained relatively unchanged in pregnant and non-pregnant mice (Table 2 ). The metabolite/parent AUC ratio is dependent on both the formation clearance (CL f ) and elimination clearance of the metabolite (CL m ). The relatively unchanged metabolite/parent AUC ratio indicates that the systemic elimination clearance of NBUP-G is increased in pregnant mice versus non-pregnant mice. The increased elimination clearance of NBUP-G in pregnant mice could be due to increased expression of Bcrp in mouse liver of pregnant mice compared to non-pregnant mice. We have previously shown that protein levels of Bcrp in the mouse liver increase ~3-fold in pregnant mice on gd 15 versus non-pregnant mice (Wang et al., 2006) . Our most recent study suggested that NBUP-G is likely a substrate of mouse Bcrp .
Hence, biliary elimination of NBUP-G could be facilitated due to increased Bcrp expression in the liver of pregnant mice. NBUP-G is also partly eliminated via renal clearance (Kacinko et al., 2009 ). Studies have shown that glomerular filtration rate (GFR) is increased by ~50% during the first trimester and continues to increase throughout pregnancy (Jeyabalan and Conrad, 2007) .
Hence, an increase in GFR during pregnancy may also contribute to the increased elimination of NBUP-G in pregnant mice. We realize that, to fully explain the PK changes of NBUP-G, it is necessary to directly investigate the mechanisms and kinetics of NBUP-G clearance in mice.
This would be a topic of investigation in future studies.
In summary, this study demonstrates that pregnancy induces total protein content of several Ugts in mice, leading to increased systemic clearance of NBUP. Our proteomic analysis revealed that hepatic Ugts are differentially regulated by pregnancy; in particular, Ugt1a1 and Ugt2b1 were significantly induced. How such a change in NBUP disposition may affect overall disposition and hence the efficacy and safety of the parent BUP during pregnancy warrants further investigation. The plasma AUC of BUP has been shown to be significantly decreased during pregnancy (Bastian et al., 2017) , and dose adjustments may be required to maintain efficacy in pregnant women. A major concern of such dose adjustments is the toxicity (e.g., respiratory depression) of the major circulating metabolite NBUP. Results of this study suggest that the toxicity of NBUP may be compensated by its increased clearance during pregnancy.
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